Table 2.
Antioxidant capacity of the hydrolysates measured by iron chelation, ABTS and DPPH radical scavenging and inhibition of lipid oxidation
| Antioxidative capacity%2 | ||||
|---|---|---|---|---|
| Sample | TEAC (mmol/L)1 Lipid oxidation inhibition3 | Iron chelation4 | ABTS5 | DDPH4 |
| Colon | 47a (CI 37–61) | 79.3 ± 3.2b | 86.4 ± 2.1a | 17.6 ± 0.3b |
| Appendix | 27b (CI 22–36) | 77.0 ± 2.3b | 84.4 ± 2.9ab | 17.1 ± 0.2b |
| Rectum | 13c (CI 9–18) | 66.5 ± 3.3c | 82.1 ± 3.8ab | 12.1 ± 0.3d |
| Pancreas | 19bc (CI 10–30) | 77.1 ± 1.8b | 84.3 ± 3.4ab | 13.4 ± 0.2c |
| Liver | 29ab (CI 22–38) | 92.0 ± 1.1a | 79.2 ± 4.2ab | 9.9 ± 0.3e |
| Lung | 22b (CI 18–24) | 38.0 ± 2.4d | 87.9 ± 4.1a | 9.7 ± 0.2e |
| Heart | 14c (CI 13–16) | 20.8 ± 9.3e | 76.5 ± 7.2b | 25.4 ± 0.3a |
| Trolox | 59.9 ± 7.8 | 13.9 ± 2.9 | ||
Values with different lowercase letters in the same column are significantly different at P < 0.05. ABTS, 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid); DPPH, 2,2-Diphenyl-1-(2,4,6-trinitrophenyl) hydrazyl; TEAC, trolox equivalent antioxidant capacity.
Values for inhibition of lipid oxidation are means with 95% confidence intervals (CI).
Values for iron chelation, ABTS, and DPPH radical scavenging are means ± standard deviations.
Inhibition of lipid oxidation was tested at 20 μL hydrolysate converted to 100% DM.
Iron chelation and DPPH radical scavenging was tested at 5 mg/mL and trolox at 0.25 mmol/L.
ABTS radical scavenging was tested at 50 μg/mL and trolox at 32 μmol/L.